Teva Completes Actavis Acquisition and Picks Up Anda, Inc. from Allergan
August 3rd 2016After divesting 79 generics businesses, the company completed its acquisition of Actavis Generics, including its over-the-counter business, on August 2. The following day, it bought Anda, Inc., the fourth largest generics distributor in the United States.
Eli Lilly CEO Announces Retirement
July 27th 2016On July 27, 2016, John C. Lechleiter, PhD, chairman, president, and CEO of Eli Lilly, announced his retirement from the company. This decision is effective December 31, 2016, however, Lechleiter will remain on the company’s board of directors until May 31, 2017 as a non-executive chairman. Lechleiter joined the company in 1979 as a senior organic chemist in process R&D. He has served as CEO of Eli Lilly since April 2008.
Powder Systems Limited Installs High-Containment Filter Dryer in Australian API Manufacturing Plant
July 26th 2016The project involves installation of a small-scale pressured agitated nutsche filter dryer in glass, integrated in a high-containment isolator to achieve an occupational exposure limit of less than 1 microgram per meter cube, 8-hour time weighted average.
Saneca Pharma Secures Contract Manufacturing Agreement with Xantis Pharma
July 26th 2016CDMO Saneca Pharma has sold registration dossiers for more than 20 pharmaceutical products to Xantis Pharma and will hold an exclusive five-year contract manufacturing agreement for the products with Xantis Pharma.
Kite Collaborates with UCLA to Develop Off-The-Shelf Allogenic T-Cell Therapies
July 26th 2016On July 25, 2016 Kite Pharma entered into an agreement with the University of California, Los Angeles, (UCLA) to advance development of off-the-shelf allogenic T-cell therapies from renewable pluripotent stem cells. The company entered into an exclusive license agreement with UCLA for an artificial thymic organoid (ATO) cell culture system. The ATO replicates the human thymic environment to support efficient ex vivo differentiation of T-cells from primary and reprogrammed pluripotent stem cells.